Haematology Research

The Haematology Research Group conducted life-saving research at the Heart Research Institute until July 2023.

Our mission is to discover new mechanisms of clot formation that can lead to the development of efficient and safer antithrombotic drugs.

We have a special interest in the development of biochips for the detection and monitoring of thrombotic tendency. We are currently investigating the application of our biochips for the detection of COVID-19 vaccine associated thrombosis thrombocytopenia, which emerged as a major concern for public safety during the roll out of COVID-19 vaccination.

In fundamental research, we are studying the role of enzymes, named thiol isomerases, in the development of thrombosis and their potential as novel antithrombotic targets. An exciting new project of our group is to define the proteomic signature of the diabetic platelet to identify causes for increased thrombotic risk in patients with diabetes. In the clinical space, we are interested in the management of venous thrombosis in the community and high-risk thrombosis.

Our research goals are to: (i) discover new targets to prevent thrombotic complications in patients with diabetes; (ii) characterise thiol isomerase inhibitors as new antithrombotics; and (iii) develop new methods to detect prothrombotic tendency in patients with cardiovascular risk factors.

Current antithrombotic treatment is not effective or has bleeding side effects, eg, one in six patients who have had a heart attack will have another attack despite optimal treatment. We aim to find answers to fundamental biological problems that will enable the development of new diagnostics and treatments for patients with blood clots.

We are committed to discovering targets for new and safe antithrombotics and to develop new assays for the diagnosis and management of thrombotic disease.